Opdualag (Nivolumab, Relatlimab)

Nivolumab, the active ingredient in Opdualag, is a monoclonal antibody presented as a strength/form for intravenous use. It treats certain advanced cancers by targeting specific immune checkpoints in adult patients. GNH USA supplies Opdualag as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

GNH USA supplies Opdualag as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Opdualag is a combination immunotherapy that acts on the PD‑1 and LAG‑3 pathways in melanoma and other solid tumours.

- Melanoma: Improves overall survival in patients with unresectable or metastatic disease. - Renal cell carcinoma: Used in combination with other agents to delay disease progression. - Non‑small cell lung cancer: Provides an additional treatment option for patients who have progressed after prior therapy. - Colorectal cancer: Used under clinical investigation — may improve response rates. - Hepatocellular carcinoma: Investigated — potential benefit — clinical trials.

This  t